Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis.

Abstract

Anti-ryanodine receptor (RyR) antibodies were measured in sera from 33 myasthenia gravis (MG) patients using three peptides from the human RyR1 sequence, two C-terminal peptides included in the functional calcium release channel, and an N-terminal peptide implicated in ion-conduction. Antibodies were more frequently positive against the two C-terminal peptides, particularly in thymoma-associated MG. In a preliminary open trial with FK506, immunosuppressant and enhancer of RyR-related sarcoplasmic calcium release, the authors observed the sustained benefits in anti-RyR-positive MG patients.

• Authors: M Takamori, M Motomura, N Kawaguchi, Y Nemoto, T Hattori, H Yoshikawa, K Otsuka
• Journal: Neurology (Neurology) Vol. 62 Issue 10 Pg. 1894-6 (May 25 2004) ISSN: 1526-632X [Electronic] United States
• PMID: 15159506 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Autoantibodies
• Autoantigens
• Epitopes
• Immunosuppressive Agents
• Receptors, Cholinergic
• Ryanodine Receptor Calcium Release Channel
• Tacrolimus

Topics

• Adult
• Aged
• Autoantibodies (blood, immunology)
• Autoantigens (chemistry, immunology)
• Combined Modality Therapy
• Enzyme-Linked Immunosorbent Assay
• Epitopes (immunology)
• Female
• Humans
• Immunosuppressive Agents (therapeutic use)
• Male
• Middle Aged
• Myasthenia Gravis (blood, drug therapy, etiology, immunology, surgery)
• Receptors, Cholinergic (immunology)
• Ryanodine Receptor Calcium Release Channel (chemistry, immunology)
• Tacrolimus (therapeutic use)
• Thymectomy
• Thymoma (complications, surgery)
• Thymus Neoplasms (complications, surgery)
• Treatment Outcome